View More Recent Stories

Mar 15, 2022 07:00AM Krystal Biotech Announces Settlement with PeriphaGen, Inc.
Feb 28, 2022 07:00AM Krystal Biotech Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Update on Operational Progress
Feb 24, 2022 07:00AM Krystal Biotech to Participate in Cowen’s 42nd Annual Health Care Conference
Jan 18, 2022 07:00AM Krystal Biotech Appoints Jing Marantz, MD, PhD, MBA as Chief Business Officer and Rand Sutherland, MD, MPH to its Board of Directors
Jan 13, 2022 04:05PM Jeune Aesthetics Leadership to Present at Octane’s 3rd Annual Aesthetics Tech Summit
Nov 29, 2021 09:30AM Pre-Open Stock Movers 11/29: (KRYS) (ADGI) (TWTR) Higher; (MRK) (UPS) Lower (more...)
Nov 29, 2021 07:05AM Krystal Biotech (KRYS) Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK in Patients with Dystrophic Epidermolysis Bullosa
Nov 29, 2021 07:00AM Krystal Biotech Announces Positive Topline Results from GEM-3 Pivotal Trial of VYJUVEK™ in Patients with Dystrophic Epidermolysis Bullosa
Nov 19, 2021 07:00AM Jeune Aesthetics to Present Pre-clinical Data Highlighting the Potential of KB303 in Elastin Production at the ASDS 2021 Virtual Meeting
Nov 8, 2021 07:00AM Krystal Biotech Reports Third Quarter 2021 Financial Results and Provides Update on Operational Progress
Oct 26, 2021 07:00AM Krystal Biotech Announces Completion of the GEM-3 Pivotal Phase 3 Study Evaluating B-VEC for the Treatment of Dystrophic Epidermolysis Bullosa
View More Recent Stories